Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (27 quarters reported)
$146M in Q4 2018 → — now. Hover for any quarter.
As reported for the quarter ended June 30, 2025. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| N N/a | NaN% | New | 0 | — |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2025 · filed August 06, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Biohaven Ltd | Exited | −2,936,507 | −$70.6M | — |
| Cytokinetics, Inc | Exited | −980,392 | −$39.4M | — |
| Biocryst Pharmaceuticals Inc | Exited | −3,846,154 | −$28.8M | — |
| Viracta Therapeutics Inc | Exited | −3,700 | −$74 | — |
| N N/a | New | +0 | — | — |
quarter ended March 31, 2025 · filed May 02, 2025
No position changes this quarter.
quarter ended December 31, 2024 · filed February 03, 2025
No position changes this quarter.
quarter ended September 30, 2024 · filed November 13, 2024
No position changes this quarter.
quarter ended June 30, 2024 · filed August 13, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Cytokinetics, Inc | New | +980,392 | +$53.1M | 29.7% |
quarter ended March 31, 2024 · filed May 08, 2024
No position changes this quarter.
quarter ended December 31, 2023 · filed February 13, 2024
No position changes this quarter.
quarter ended September 30, 2023 · filed November 13, 2023
No position changes this quarter.
Loading...
